CAS:
694499-26-8
Molecular
Formula: C13H18F3N3
Molecular
weight:273.30
Ponatinib
is an orally bioavailable multitargeted receptor tyrosine kinase (RTK)
inhibitor with abeyant antiangiogenic and antineoplastic activities. Ponatinib
inhibits unmutated and all mutated forms of Bcr-Abl, including T315I, the awful
biologic therapy-resistant missense alteration of Bcr-Abl. This abettor aswell
inhibits added tyrosine kinases including those associated with vascular
endothelial advance agency receptors (VEGFRs) and fibroblast advance agency
receptors (FGFRs); in addition, it inhibits the tyrosine kinase receptor TIE2
and FMS-related tyrosine kinase receptor-3 (Flt3). RTK inhibition by ponatinib
may aftereffect in the inhibition of cellular admeasurement and angiogenesis
and may abet corpuscle death. Bcr-Abl is a admixture tyrosine kinase encoded by
the Philadelphia chromosome.
No comments:
Post a Comment